Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
about
The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker valueTargeting of erbB3 receptor to overcome resistance in cancer treatmentA novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activityAn intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.MicroRNA regulation and therapeutic targeting of survivin in cancer.miRNA - Therapeutic tool in breast cancer? Where are we now?Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cellsFlexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.MiR-148a inhibits angiogenesis by targeting ERBB3.The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cellsp38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinomaResveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis.The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
P2860
Q26782620-BFD5DD53-EB77-4B3A-9B3D-A77237F91658Q26864668-2F45B276-4DAD-4BB0-9191-79CD33499DA0Q28483886-414FAB08-78E4-4400-83EE-247B7E6857F2Q28485864-6C4FF687-041B-4CEA-B70C-AAF77D61776CQ33412770-8E17D0D3-6ABB-4092-BBC8-C7E008582409Q33739267-BEA0C717-1BA6-4158-8F66-1D10EE912A7AQ33934617-5468ABD4-583B-462B-AB2E-6B6FCA09B0D3Q34991312-9387F4BE-EE82-49AF-AB68-351D7D814477Q35113386-453EC06C-FD39-4B92-A4F0-09FEBC630905Q35709343-1C8F5297-B8BA-4235-9A10-C26B10CAD73DQ35914683-9FD7055B-0CE3-461B-B7E4-2884D690DB78Q35918911-ED28FEBC-01BF-4F64-AA95-ABA56041C1D8Q36071752-69496A05-126D-43ED-814F-18D2F94D8DB8Q36107033-F5F49094-2F20-4494-83B8-14826185AE97Q36387554-EA676B54-5ECD-4794-8B47-6C3D37AB2ED0Q36683208-0BC68F0A-F61A-4868-B263-495A5AE8A189Q36771985-27FB0702-1762-4CD4-872D-C4B8FAD37F78Q36946749-12FEF512-2626-43F8-9E05-89578CF861A9Q37129819-6885FA1B-E886-4678-A5B1-1C09898F7B4EQ37164515-4FF643B1-89F7-4CEC-937E-4AEBF2BA94D1Q37312071-24BED465-1FCA-4F03-A8D9-24321EDF94D8Q37437269-EA27C21A-01D9-47F7-BEF4-490DE6A80851Q37690272-9EC1659D-65B7-471D-B31B-175F5863A93DQ37692080-585C9F32-4BAB-49DB-B981-92FCD34DC165Q38623361-580622C4-88C2-48B0-9502-7B1114E9408AQ38729111-11DBC931-D7E7-4CC4-B316-160D71FDAA44Q38743426-B9A9D233-A2CF-445E-86F2-CC178324FF82Q38834921-B3A1EFF1-4B77-495F-8D30-5474FDEB5019Q38867798-856D2C47-AE1D-4CE9-9476-2987DBFE74B9Q38883702-FF1FC403-8F63-4687-A356-36595E81C3E2Q38929801-A9D8B1AB-6C40-4A74-B60D-8E6831D601B0Q38996033-35552BDB-D39C-4177-AD59-C094CD74A471Q39177415-210457CD-4A1A-4108-BC65-68231635E72FQ39418429-F07CF604-9BEF-4124-96DF-6D636AAD9DEBQ54945951-6711D20D-6392-4722-933B-CA3599B0AA82Q58796351-91217532-B25A-4B09-9266-9A71EA584A2F
P2860
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@ast
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@en
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@nl
type
label
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@ast
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@en
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@nl
prefLabel
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@ast
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@en
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@nl
P2093
P3181
P356
P1433
P1476
Elevated expression of erbB3 c ...... s via upregulation of Survivin
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/ONC.2010.180
P407
P50
P577
2010-05-24T00:00:00Z
P6179
1028021238